Balance Sheet
Cash Flow Statement
AmortizationAmortizationAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Divestments (2019 - 2023)

Legend Biotech (LEGN) posted Divestments of $407.5 million for Q4 2023, up 1534.48% on a QoQ basis from $24.9 million in Q4 2022, and up 1534.48% year-over-year from $24.9 million in Q4 2022.

Legend Biotech (LEGN) has 5 years of Divestments data on file, last reported at $407.5 million in Q4 2023.

  • In Q4 2023, Divestments rose 1534.48% year-over-year to $407.5 million; the TTM figure through Dec 2023 stood at $590.1 million (up 99.32% YoY), while the FY2023 annual figure was $92.8 million, up 220.36% from the prior year.
  • Divestments climbed to $407.5 million in Q4 2023, from $24.9 million in the prior quarter.
  • Across five years, Divestments topped out at $407.5 million in Q4 2023 and bottomed at $24.9 million in Q4 2022.
  • A 5-year average of $140.7 million and a median of $96.5 million in 2021 frame the typical range for Divestments.
  • Annual changes were most pronounced in 2022 — Divestments sank 74.17% — and 2023, when it soared 1534.48%.
  • Year by year, Divestments stood at $113.5 million in 2019, then sank by 46.09% to $61.2 million in 2020, then soared by 57.79% to $96.5 million in 2021, then sank by 74.17% to $24.9 million in 2022, then soared by 1534.48% to $407.5 million in 2023.
  • The last three Divestments figures came in at $407.5 million (Q4 2023), $24.9 million (Q4 2022), and $96.5 million (Q4 2021), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Divestments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Revolution Medicines 32.39 Bn 32.39 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2023 407.51 Mn
Dec 31, 2022 24.93 Mn
Dec 31, 2021 96.51 Mn
Dec 31, 2020 61.17 Mn
Dec 31, 2019 113.45 Mn